

IN THE CLAIMS

Please amend claims 44-46 as follows:

1. – 30. (Canceled)

31. (Previously Presented) A synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and which comprises the nucleotide sequence shown in SEQ ID NO: 10, wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide.

32. – 35. (Canceled)

36. (Withdrawn) The synthetic oligonucleotide of claim 31, wherein the oligonucleotide is up to 70 nucleotides in length.

37. (Withdrawn) The synthetic oligonucleotide of claim 31, wherein the oligonucleotide is up to 50 nucleotides in length.

38. (Canceled)

39. (Withdrawn) The synthetic oligonucleotide of claim 31, wherein the oligonucleotide is 30 nucleotides in length.

40. (Canceled)

41. (Canceled)

42. (Canceled)

43. (Withdrawn) A pharmaceutically acceptable salt of a synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide.
44. (Withdrawn) A pharmaceutically acceptable salt of the synthetic oligonucleotide of claim 31.
45. (Withdrawn) A pharmaceutically acceptable salt of the synthetic oligonucleotide of claim 39.
46. (Currently Amended) A pharmaceutical composition comprising a synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide, and a pharmaceutically acceptable carrier.
47. (Withdrawn) A pharmaceutical composition comprising the synthetic oligonucleotide of claim 31 and a pharmaceutically acceptable carrier.
48. (Withdrawn) A pharmaceutical composition comprising the synthetic oligonucleotide of claim 39 and a pharmaceutically acceptable carrier.
49. — 50. (Canceled)